Halozyme Therapeutics (HALO) Retained Earnings (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Retained Earnings of -$12.7 million for Q1 2026, down 102.66% year-over-year from $478.0 million in Q1 2025, and down 123.19% quarter-over-quarter from $54.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Retained Earnings (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Retained Earnings for 17 consecutive years, with -$12.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 102.66% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$12.7 million (down 102.66% YoY), while the FY2025 annual figure was $54.8 million, up 1330.82% from the prior year.
- Retained Earnings eased to -$12.7 million in Q1 2026 per HALO's latest filing, from $54.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $502.1 million in Q3 2025 and bottomed at -$28.4 million in Q2 2025.
- Historically, Retained Earnings has averaged $68.7 million across 5 years, with a median of $24000.0 in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 13014.29% — and 2024, when it jumped 697287.5%.
- Halozyme Therapeutics' Retained Earnings stood at -$922000.0 in 2022, then slumped by 906.29% to -$9.3 million in 2023, then surged by 141.27% to $3.8 million in 2024, then soared by 1330.82% to $54.8 million in 2025, then plunged by 123.19% to -$12.7 million in 2026.
- Business Quant data shows HALO's Retained Earnings at -$12.7 million in Q1 2026, $54.8 million in Q4 2025, and $502.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 151.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.26 Mn |
| Mar 31, 2026 | -12.70 Mn |
| Dec 31, 2025 | 54.79 Mn |
| Sep 30, 2025 | 502.15 Mn |
| Jun 30, 2025 | -28.40 Mn |
| Mar 31, 2025 | 477.96 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | -6.94 Mn |
| Jun 30, 2024 | -2.07 Mn |
| Mar 31, 2024 | 167.37 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | 1.23 Mn |
| Jun 30, 2023 | -1.62 Mn |
| Mar 31, 2023 | 24,000.00 |
| Dec 31, 2022 | -922,000.00 |
| Sep 30, 2022 | -1.84 Mn |
| Jun 30, 2022 | 23.88 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | -620,000.00 |
| Sep 30, 2021 | -14,000.00 |